Assembly Biosciences vs Kura Oncology
Assembly Biosciences reported revenue of $72 million in fiscal 2025, about the same as Kura Oncology's $68 million in fiscal 2025. Assembly Biosciences' revenue grew 153.5% in its latest year, and Kura Oncology's grew 25.2%. Assembly Biosciences had an operating margin of -16.8%, against -449.9% at Kura Oncology. Free cash flow was −$41 million at Assembly Biosciences and −$71 million at Kura Oncology.
Side by side
| Assembly Biosciences | Kura Oncology | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $72M | $68M |
| Revenue growth | 153.5% | 25.2% |
| Revenue growth a year, last 5 years | −1.8% | — |
| Gross margin | — | — |
| Operating margin | −16.8% | −449.9% |
| Net margin | −8.5% | −412.9% |
| Free cash flow | −$41M | −$71M |
| Free cash flow margin | −56.9% | −104.8% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 86.7% | 1.8% |
| Last close | $22.50 | $7.35 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $14,687 | bought $3.9 million, sold $4.0 million |
| Piotroski F-score | — | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Assembly BiosciencesKura Oncology
Operating margin
Percent of revenue
Assembly BiosciencesKura Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Assembly BiosciencesKura Oncology
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Assembly Biosciences and Kura Oncology pages.